Genesis Drug Discovery and Development (GD3), a member of the Genesis Biotechnology Group is a contract research organization focused on providing services to support preclinical drug discovery programs from early discovery through preclinical development. The Company’s diversified portfolio of services covers all areas of preclinical drug discovery/development including “Discovery Biology”, “Synthetic Organic and Medicinal Chemistry”, DMPK/in-vivo pharmacology and Toxicology. GD3’s capabilities cover a wide range of therapeutic areas including oncology, ophthalmology, inflammation/autoimmunity, metabolic diseases and microbiome